 CAMBRIDGE, Mass, July 29, 2021 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a development-stage biotechnology company leveraging its OMEGA Epigenomic ProgrammingTM platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of 17.00 per share. All of the shares of common stock are being offered by Omega. 